Офлоксин (Ofloxacin) is used for managing conditions characterized by periods of heightened symptoms stemming from bacterial infections across several major therapeutic domains. It contributes to easing the overall symptom load and is applied when appropriate for the underlying bacterial cause.

---

Therapeutic Use and Symptom Relief

This medication is relevant for addressing symptoms related to inflammatory or irritative states in both localized and systemic contexts. Clinically, it is commonly used for conditions presenting with acute episodes of bacterial origin, including complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, certain sexually transmitted diseases, bacterial conjunctivitis, and otitis externa. This medication is relevant for managing symptoms that interfere with daily comfort.

Офлоксин provides support that helps ease the overall symptom burden in these scenarios. It is applied when symptoms interfere with daily comfort, contributing to improved comfort during periods of heightened discomfort and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Painful Symptoms Ofloxacin is relevant for easing discomfort symptoms such as painful urination associated with cystitis and localized discharge and pain stemming from acute ocular or otic infections.

Regulatory References

1. NIH MedlinePlus overview of Ofloxacin's therapeutic uses

Who Can and Cannot Use Ofloxacin (Офлоксин)?

Population eligibility for systemic Ofloxacin is defined by regulatory contraindications and restrictions related to its classification as a fluoroquinolone antibiotic.

Absolute Contraindications

Use is strictly prohibited in several populations according to official regulatory documentation:

• Patients with a known history of hypersensitivity to Ofloxacin or to any other fluoroquinolone antibacterial agent.
• Individuals with a history of epilepsy or an existing central nervous system disorder associated with a lowered seizure threshold.
• Patients with a history of tendon disorders related to previous fluoroquinolone administration.
• Pregnant women and breastfeeding women.

Age and Conditional Use Restrictions

Systemic Ofloxacin is contraindicated for children and growing adolescents (generally under 18 years) [Source 2.3]. The medicine is approved for use in adults.

Specific conditions require caution or restriction:

• Renal Impairment: Patients with impaired kidney function remain eligible, but use requires a reduced maintenance dose to prevent drug accumulation.
• Severe Hepatic Dysfunction: Use requires caution and monitoring, often necessitating a restriction on the maximum daily dosage.
• Elderly Patients: Use requires caution due to an increased risk of tendon rupture and aortic events, and a higher prevalence of reduced renal function.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ofloxacin across specific pharmacokinetic and pharmacodynamic categories, resulting in mandatory restrictions for co-administration.

---

Interaction Scope and Restrictions

Category (Regulatory Focus)	Official Constraint or Outcome
Formal Contraindication	Co-administration with Tizanidine is contraindicated due to a pharmacokinetic interaction that significantly increases Tizanidine exposure (AUC).
Cardiac Risk Restriction	Restricted use with medicines known to prolong the QT interval (e.g., specific antiarrhythmics, macrolides) due to a documented additive pharmacodynamic effect.
Exposure-Modifying Agents	Ofloxacin may increase the plasma concentration of co-administered medicines such as Theophylline and Cyclosporin by reducing their clearance.
Renal Competition	Substances eliminated by renal tubular secretion (e.g., Probenecid, Methotrexate) may be affected, leading to reduced clearance of Ofloxacin or the co-administered agent.

---

Timing and Additive Risks

Official labeling mandates a timing separation for co-administration with products containing multivalent cations (e.g., antacids, iron salts, zinc). These agents must be administered at least two hours before or two hours after Ofloxacin to prevent a documented reduction in Ofloxacin absorption.

Pharmacodynamic interactions include an increased risk of tendon rupture when co-administered with Corticosteroids, and potentiation of the anticoagulant effect of Warfarin (Vitamin K Antagonists). Patients with renal impairment are noted in regulatory information as having heightened risk for accumulation and interaction due to reduced clearance.

How Офлоксин Works

Dual Targeting of Bacterial DNA Gyrase and Topoisomerase IV

Ofloxacin exerts a bactericidal effect by disrupting the bacterial cell's fundamental genetic processes. Its primary mechanism involves binding to and inhibiting two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for managing the topological structure of the bacterial DNA, including supercoiling and chromosome separation during replication. By inhibiting these targets, Ofloxacin physically locks the enzymes onto the bacterial genome, preventing them from repairing the DNA and clearing the way for replication.

Mechanistic Cascade Leading to Irreversible DNA Damage

The trapping of the enzyme-DNA complex leads to the accumulation of irreparable double-strand DNA breaks within the bacterial cell. This genetic damage is irreversible, triggering a rapid and irreversible cellular cascade that halts all essential metabolic functions, including DNA synthesis and cell division. This definitive bactericidal effect ensures the complete physiological destruction and elimination of the susceptible pathogen population.

Limitations via Bacterial Efflux and Target Modification

The efficacy of Ofloxacin's mechanism is physiologically constrained by bacterial countermeasures. Its action can be weakened if bacteria develop mutations that alter the structure of the target enzymes, thus reducing the drug's binding affinity. Additionally, the overexpression of efflux pumps allows bacteria to actively transport the Ofloxacin molecule out of the cell, preventing it from reaching the necessary intracellular concentration to execute its lethal mechanism.

How to Use Ofloxacin: Administration Guidelines

Administration Scope

Usage Entity	Instruction
Route of Administration	Oral (for systemic tablets) and Topical (0.3% solution for ophthalmic/otic use).
Dosing Schedule	Standard adult systemic doses range from 200 mg to 400 mg per intake. The maximum daily dose generally should not exceed 800 mg.
Frequency	Doses up to 400 mg daily may be taken as a single dose. Higher daily doses are administered in two divided doses (e.g., every 12 hours).
Timing Relative to Meals	Oral tablets may be taken with or without food.

---

Special Procedural Conditions

Co-administration Constraint: Ofloxacin absorption can be reduced by certain metallic supplements and antacids. Therefore, the oral tablet must be taken two hours before preparations containing magnesium/aluminum antacids, sucralfate, iron, or zinc.

Tablet Intake: Oral tablets must be swallowed whole with sufficient liquid.

Otic Preparation: The otic (ear) solution should be warmed prior to instillation to minimize the potential for dizziness.

Treatment Duration: The course of treatment varies widely, ranging from a single dose for specific acute conditions up to a maximum systemic duration that generally should not exceed two months.

---

Population-Specific Adjustments

Impaired Organ Function: Dosage adjustment is required for patients with renal impairment (creatinine clearance leq 50 mL/min), with maintenance doses typically reduced. The daily dose generally should not exceed 400 mg for patients with severe hepatic dysfunction.

These instructions define the precise route, form, dose, and specific administration constraints necessary for using Ofloxacin, establishing the standardized administration procedures.

Research Evidence / Overview of Studies for Офлоксин

This section provides a summary of the official research, including key randomized controlled trials (RCTs), systematic reviews, and meta-analyses, that was studied for Офлоксин (Ofloxacin). This is a purely descriptive overview of the evidence base, not clinical advice or treatment guidance.

---

Evidence for Use in Systemic Infections

This section describes the structure of the clinical trials and comparative studies that research examined the oral use of Офлоксин for internal body infections, including certain urinary tract issues and acute respiratory conditions.

Evidence for Urinary Tract Infections (UTIs)

Findings data show patterns related to the short-term rate of observed changes in acute symptoms and the observed status of targeted bacteria in complicated UTIs. The research consistency for complicated UTIs is generally described by regulators as categorized as High. The use of this antibiotic class for uncomplicated UTIs is restricted in specific scenarios by some regulatory bodies, reflecting the need for careful tracking of resistance development.

Evidence for Respiratory and Pelvic Infections

For Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB), the trials findings describe patterns observed in the studies related to the observed changes in acute respiratory symptoms. The research consistency is categorized as High. Official regulatory perspectives note that this antibiotic class should be reserved for use in this condition when other treatment options are not viable. For Pelvic Inflammatory Disease (PID), research studies report how symptoms evolved in the observed populations, but because many studies involve combination therapy, the research consistency is categorized as Moderate, and comparative evidence is less extensive for the single use of Офлоксин alone.

---

Evidence for Use in Localized Topical Infections

Evidence for Ocular (Eye) Infections

Topical ophthalmic use was studied for adults and children with bacterial eye infections. The trials findings describe patterns observed in the studies related to the rate of clinical sign resolution and pathogen clearance. The evidence base for this topical use consistency is categorized as High.

Evidence for Otic (Ear) Infections

Research data show patterns related to symptom clearance, particularly the stopping of ear discharge. This body of evidence consistency is also categorized as High. It is important to note that since the administration is local, results apply only to the populations studied and are not applicable to systemic infections.

---

What Remains Uncertain About Офлоксин Research

The main research limitations include that follow-up durations were limited in many of the initial trials, meaning long-term effects are not fully established. Evidence quality varies across studies for less common indications, and subgroup findings are uncertain. Official guidance from regulatory bodies indicates that this antibiotic class should be reserved for use in certain cases, reflecting a need to balance short-term findings with long-term surveillance data.

Common questions about Офлоксин (FAQ)

---

Q: Can I take Офлоксин if I'm currently taking a vitamin supplement?

Official product information advises separating the administration of Офлоксин from certain supplements. Products containing multivalent cations, such as iron, zinc, calcium, or magnesium, should be taken at least two hours before or two hours after the antibiotic. This is done because these mineral supplements can significantly reduce the amount of the drug the body absorbs.

---

Q: Can elderly patients use Офлоксин safely?

According to regulatory documentation, use in elderly patients is permitted under specific conditions but is subject to caution, as noted in official warnings. This is primarily due to an increased risk of certain serious side effects in this population, such as tendon rupture and aortic events. Official guidance emphasizes the need for close observation by a healthcare professional during treatment.

---

Q: Is it safe to drink coffee while taking Офлоксин?

Official information does not typically list coffee as a formal restriction. However, the official product information documents the drug's potential to alter the way the body processes certain compounds. This includes the processing of substances like theophylline, which is chemically related to caffeine.

---

Q: Does Офлоксин interact with dairy products?

Official guidance states that taking the drug simultaneously with dairy products or calcium-containing antacids may reduce the drug's effectiveness. A timing separation of two hours before or two hours after is noted in the official guidance. This is a constraint imposed because the calcium in these products can significantly bind to the drug.

---

Q: What are the official guidelines regarding sun exposure while on Офлоксин?

Official safety information lists photosensitivity as a potential adverse reaction of Офлоксин. Photosensitivity is an abnormal sensitivity to light, particularly sunlight. Because of this potential effect, official labeling emphasizes the need to be aware of sun and UV light exposure.

---

Q: How does Офлоксин differ from other drugs in the same class?

Офлоксин is recognized in medical literature as a second-generation fluoroquinolone antibiotic. Research examined its spectrum of activity against a range of bacteria. Its specific activity profile and pharmacokinetic properties are themes noted in the relevant scientific literature that inform its use.

---

Q: What happens if I miss a dose of Офлоксин?

Official instructions describe the procedure for a missed dose: it may be taken as soon as it is remembered. However, if it is close to the time for the next dose, the official guidance indicates that the missed dose should be skipped entirely to maintain the regular dosing schedule.

---

Q: Is it true that Офлоксин can affect blood sugar levels?

Yes, official regulatory information confirms that Офлоксин can affect blood glucose (sugar) control. Reports associated with the use of the drug have included instances of both dangerously low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia).

---

Q: Is Офлоксин considered a broad-spectrum medicine?

Yes, the medicine is formally described in official regulatory documents as a synthetic broad-spectrum antimicrobial agent. This classification means it is designed to be effective against a wide variety of bacterial strains.

---

Q: Does the medicine cause changes in sleep patterns?

Official documentation lists sleep problems, including insomnia (trouble sleeping), as a common potential side effect. This is related to the drug’s potential influence on the central nervous system, which is noted within the drug’s safety profile.

---

Q: Are there known differences in how Офлоксин affects men versus women?

Pharmacokinetic studies, which describe how a drug is processed by the body, have suggested that women may experience a greater systemic exposure (higher concentration in the blood) to the drug than men when receiving the same dosage. These observed differences in how the drug is processed are part of the overall safety and pharmacokinetic data reviewed by regulators.

---

Q: What are the official recommendations regarding alcohol consumption while on Офлоксин?

Regulatory documents and related safety reviews do not typically cite alcohol as a formal contraindication for this medicine. Unlike some other antibiotics, there is generally no specific warning regarding alcohol consumption mandated by major regulatory bodies.

---

Q: Is the medication known by any other trade names?

Yes, the active ingredient Ofloxacin is marketed globally under various brand names, as indicated in regulatory listings. Common examples include Floxin for systemic use (oral tablets) and Ocuflox for localized topical use (eye or ear drops).

---

Q: Do official documents mention the need for dosage adjustment based on weight?

Official regulatory documents define standard adult dosages based on the specific infection being treated. Dosage adjustments are required primarily for patients with impaired organ function (such as kidney or liver issues), and are not based on the patient's body weight.

How to Store and Dispose of Ofloxacin

To ensure product stability, Ofloxacin (tablets and solutions) must be stored at controlled room temperature, typically between 15 C and 25 C (59 F and 77 F). The medication should be kept in its original container, tightly closed, and stored away from moisture, heat, and direct light.

Key Storage and Handling Requirements

• Do not freeze liquid formulations, as this may compromise the product.
• Always keep Ofloxacin out of the reach of children.

Disposal Guidelines

• Do not flush unused or expired medication down the toilet or pour it down a drain unless specifically instructed by a healthcare professional.
• To properly dispose of medicine no longer needed, consult your pharmacist or local waste disposal company for guidance on community drug take-back programs or safe disposal methods.
• Disposal should adhere to all local and governmental regulations to prevent environmental contamination.